欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Quikin CAR-T Platform


The Quikin CAR-T Platform (Quikin CART) generates T cell products with gene knockout and stable integration of CAR cassette in one step through CRISPR gene editing technology. As a new generation of CAR-T platform, it has several advantages, including simplified manufacturing process, shortened preparation time, higher product uniformity and avoiding the risk of tumorigenesis caused by random integration. The product with integration of anti-CD19 CAR cassette into PD1?locus combines PD1 immune checkpoint inhibition with CART anti-tumor activity. This platform has the potential to prepare enhanced CAR-T cells with gene knockout of multiple immune checkpoints, rapidly produce universal CAR-T cells and prepare dynamically regulated CAR-T cells with high safety, thus providing strong technical support for future improvement of CAR-T cells.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 欧美成人版中文字幕 | 国产成人精品高清免费 | 亚洲国产精品自产拍在线播放 | 国产成人久久综合一区77 | 99久久精品免费精品国产 | 国产三级aⅴ在线观看 | 亚洲a在线观看 | 欧美精品香蕉在线观看网 | 国产菲菲视频在线观看 | 久久久国产99久 | 欧美黑吊 | 国语最新自产拍在线观看 | 国产h视频在线观看免费 | 免费观看国产一区二区三区 | 97久久人人超碰超碰窝窝 | 影视少妇综合欧美 | 在线观看人 | 欧美日韩一区二区二区 | 成人午夜精品无码区久久中文 | 欧美黑人性受xxxx精品 | 最新中文字幕在线 | 亚洲国产精品浪潮久久久av | 国产精品成熟 | 日本熟女多毛性爱 | 成在人线av无| 久久精品中文字幕有码日本道 | 亚洲国产天堂久久综合网站 | 欧美日韩视频在线观看第一区 | 国产在线国 | 久久美女精品福利视频 | 国产午夜精品美女短视频 | 免费黄片视频在线观看 | 亚洲欧美日本人成在线观看 | 午夜欧美一级电影 | 狠狠干狠狠操 | 午夜电影一区 | 国内精品自在自线在免费 | 人人妻人人澡人人爽欧美精品 | 成人午夜精品无码区 | 色综合无码黑 | 99视频在线精品自拍 |